celecoxib has been researched along with Multiple Myeloma in 1 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prince, HM | 1 |
| Mileshkin, L | 1 |
| Roberts, A | 1 |
| Ganju, V | 1 |
| Underhill, C | 1 |
| Catalano, J | 1 |
| Bell, R | 1 |
| Seymour, JF | 1 |
| Westerman, D | 1 |
| Simmons, PJ | 1 |
| Lillie, K | 1 |
| Milner, AD | 1 |
| Iulio, JD | 1 |
| Zeldis, JB | 1 |
| Ramsay, R | 1 |
1 trial available for celecoxib and Multiple Myeloma
| Article | Year |
|---|---|
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; An | 2005 |